Carboplatin 150mg
| Product Overview | |
| Generic Name | Carboplatin 150mg |
| Brand Name(s) | Paraplatin |
| Form | Vial, injectable solution |
| Strength | 150 mg |
| Therapeutic Class | Platinum-based antineoplastic alkylating agent |
| ATC Code | L01XA02 |
| Manufacturing & Regulatory | |
| Manufacturer | Generics, |
| Country | Canada, USA, India, Mexico |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Type II/III DMFs |
| COFEPRIS | 010.000.4431.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 36 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request, not publicly posted |
| CTD Summary | Not publicly available as parallel traded molecule |
Description
Carboplatin is a platinum-based antineoplastic agent used in the treatment of various solid tumours. It acts by forming DNA crosslinks, thereby inhibiting DNA replication and tumour cell proliferation. Carboplatin is commonly used in ovarian cancer, lung cancer, head and neck cancers, testicular cancer, bladder cancer, and other malignancies where platinum-based chemotherapy is clinically indicated
